Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 220 clinical trials
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW)

The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with

systemic therapy
sorafenib
nivolumab
lenvatinib
  • 74 views
  • 15 Jun, 2022
  • 23 locations
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC (SUNIFORECAST)

SUNNIFORECAST (Standard of Care vs. Nivolumab + Ipilimumab as First line treatment of renal cell cancer of non-clear cell subtypes) is a Phase II, randomized, open-label investigator initiated

metastasis
sunitinib
measurable disease
nivolumab
clear cell renal cell carcinoma
  • 116 views
  • 15 Mar, 2022
  • 34 locations
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with

atezolizumab
measurable disease
karnofsky performance status
metastatic renal cell carcinoma
monoclonal antibodies
  • 319 views
  • 16 Jun, 2022
  • 347 locations
Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

This phase I trial studies the side effects of nivolumab and ipilimumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is

nitrosoureas
interleukins
tumor progression
antineoplastic
monoclonal antibodies
  • 72 views
  • 03 May, 2022
  • 17 locations
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC)

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

measurable disease
carcinoma
ipilimumab
  • 280 views
  • 27 Jan, 2022
  • 29 locations
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (CheckMate 9N9)

The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or

nivolumab
metastatic colorectal cancer
colon cancer
  • 278 views
  • 14 Jun, 2022
  • 35 locations
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.

measurable disease
ipilimumab
  • 13 views
  • 15 May, 2022
  • 13 locations
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in

lung carcinoma
chemoradiotherapy
nivolumab
durvalumab
  • 28 views
  • 05 Jun, 2022
  • 127 locations
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

This study is to compare and evaluate the efficacy and safety of ONO-4538 in combination with ipilimumab and chemotherapy versus chemotherapy in chemotherapy-naïve participants with HER2

adenocarcinoma
erbb2
capecitabine
oxaliplatin
cancer chemotherapy
  • 0 views
  • 19 Jun, 2022
  • 46 locations
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)

administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet), and nivolumab + bempegaldesleukin (triplet) in subjects with advanced solid tumors. In the Expansion

programmed cell death 1 ligand 1
measurable disease
systemic therapy
karnofsky performance status
monoclonal antibodies
  • 0 views
  • 25 Apr, 2022
  • 1 location